Grivas Expands on Key Data From the 2023 ESMO Congress in Urothelial Cancer : vimarsana.com

Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.

Related Keywords

Petros Grivas , University Of Washington School Medicine , Genitourinary Cancers Program , Clinical Research Division At Fred Hutch , Division Of Medical Oncology , Science Summit , Medical Oncology , Washington School , Clinical Research Division , Fred Hutch , Fred Hutch Cancer Center , Urothelial Cancer , News ,